SLC5A2 and heart failure: However, a recent RCT, PRESERVED-HF, aimed to explore the clinical benefits of SGLT2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF) and found that the HFF rate was 5.6% in both the SGLT2 inhibitor-treated and control groups (13).